Serum Institute of India to resume Oxford-AstraZeneca COVID-19 vaccine trials; gets DCGI nod
Published
The Drugs Controller General of India (DCGI) has allowed the Serum Institute of India (SII) to resume its phase two and three clinical trials for the Oxford-AstraZeneca COVID-19 vaccine.
Full Article